Life launches genomics spinoff with Boston Children's Hospital

Tools
Ion Proton Sequencer--courtesy of Life Technologies.

Life Technologies ($LIFE) is partnering with Boston Children's Hospital to launch Claritas Genomics, a joint venture that will develop genomics-based diagnostics.

The hospital will own a majority stake, Life said, and the new company will operate out of Boston Children's CLIA-certified diagnostic lab, using Life's Ion Proton Sequencer to develop molecular diagnostics ready for scale-up and marketing.

For Life, the JV is the latest in a slew of acquisitions and team-ups over the past 12 months, all designed to expand the company's technology and speed the development of assays and companion diagnostics, CEO Greg Lucier said.

"Our investment in Claritas Genomics is a prime example of strategic partnerships Life Technologies is entering into to accelerate the use of accurate genomic information in medical practice," Lucier said in a statement. "This new venture serves as a model for future endeavors to demonstrate the validation of our Ion Torrent technology in an integrated laboratory workflow designed for clinical applications related to pediatrics and inherited diseases."

Boston Children's plans to use Claritas to build on its existing genomic discovery efforts and eventually translate that research into diagnostic solutions, David Margulies, the hospital's director of gene partnership, said in a statement.

- read the announcement

Related Articles:
Life buys bioinformatics company to boost Dx development
Life Technologies, CollabRx forge molecular Dx data deal
Life Technologies reels in Bristol-Myers Squibb as companion Dx partner